EGFR exon 20 mutant inhibitor, oral once-daily Breakthrough Therapy for ex20+ NSCLC (Ph. I) from cellular screening + SBDD Cancer Discovery, Feb. 25, 2021 ARIAD/Takeda, Cambridge, MA